

Capital Rx Drug Recall Report

APRIL 2025



Welcome to the **Capital Rx Drug Recall Report**. This report is designed to keep you up to date on the latest FDA Class 1 and Class 2 recalled drugs and market withdrawals that impact our members. It is one of the many ways we, at Capital Rx, demonstrate our commitment to providing clients and partners the tools and resources they desire.

WHO WE ARE

Capital Rx is a full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA), advancing our nation's electronic healthcare infrastructure to improve drug price visibility and patient outcomes. Capital Rx is executing its mission through the deployment of Judi®, the company's cloud-native enterprise health platform, and a Single-Ledger Model™, which increases visibility and reduces variability in drug prices. Judi connects every aspect of the pharmacy ecosystem in one efficient, scalable platform, servicing over 2.4 million members for Medicare, Medicaid, and commercial plans. Together with our clients, we are reimagining the administration of pharmacy benefits and rebuilding trust in healthcare. **The drug recall report is subject to change: information in this report is current as of **4/9/2025****

Privacy Statement:

This privacy policy describes the types of information we may collect from you or that you may provide when you visit the website cap-rx.com and our practices for collecting, using, maintaining, protecting, and disclosing that information. Capital Rx, Inc. ("we," "our," or "us") is committed to ensuring that your privacy is protected. This policy applies to information we may collect through cap-rx.com, including any services offered on or through cap-rx.com such as the prescription benefit member web portal, and our mobile application accessible at the Google Play Store and iOS App Store under the name Capital Rx (collectively, our "Site").

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
03/26/2025	Class 2	Cinacalcet HCL 30 Mg Tablets	Slate Run Pharmaceuticals	70436-0007-04	07711, EXP 07/2025; 08900, EXP 09/2026; 08899, EXP 09/2026	Deviations from the Current Good Manufacturing Practices (CGMP). An impurity called nitrosamine was higher than the acceptable limit.
03/26/2025	Class 2	Cinacalcet HCL 60 Mg Tablets	Slate Run Pharmaceuticals	70436-0008-04	109797, EXP 11/2026	Deviations from the Current Good Manufacturing Practices (CGMP). An impurity called nitrosamine was higher than the acceptable limit
03/26/2025	Class 2	Neupogen 300 MCG/ML Solution	Amgen, Inc.	55513-0530-01, 55513-0530-10	1147300, 1147300A, EXP 2/28/2025; 1152064, EXP 3/31/2025; 1154734, 1156806, EXP 8/31/2025; 1159109, EXP 10/31/2025; 1163909, EXP 2/28/2026; 1164631, EXP 5/31/2026; 1171366, 1182097, EXP 8/31/2026; 1176114, EXP 2/28/2027; 1182094, EXP 7/31/2027	Failing stability tests showing the product may not stay safe or effective for the full 36 months. It might not meet quality standards by the time it expires.

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
03/26/2025	Class 2	Prasugrel HCL 5 Mg Tablets	MYLAN PHARMACEUTICALS INC	00378-5185-93	3211073, 3211074, 3211075, EXP 4/30/2026	Failing to meet dissolution specifications, which may result in the tablets not dissolving properly
4/2/2025	Class 2	Testosterone 25 Mg/2.5gm (1%) Gel	Strides Pharma, Inc.	64380-0151-02	5501127A, 5501236A, EXP APR-25; 5501341A, EXP JUN-25; 5501406A, EXP JUL-25; 5501408A, EXP AUG-25; 5501516A, EXP SEP-25; 5501568A, EXP OCT-25; 5501829A, EXP MAR-26; 5502000A, EXP JUL-26; 5502004A, 5502005A, EXP AUG-26; 5502092A, EXP OCT-26; 5502217A, EXP DEC-26; 5502262A, EXP JAN-27	The presence of a foreign substance, Benzene, in the product
4/2/2025	Class 2	Testosterone 50 Mg/5gm (1%) Gel	Strides Pharma, Inc.	64380-0152-02	5501103A, EXP MAR-25; 5501237A, 5501238A, EXP APR-25; 5501278A, EXP MAY-25; 5501280A, 5501342A, EXP JUN-25; 5501372A, EXP JUL-25; 5501496A, EXP AUG-25; 5501499A, EXP SEP-25; 5501580A, EXP OCT-25; 5501582A, EXP DEC-25; 5501653A, 5501656A, EXP JAN-26; 5501770A, EXP FEB-26; 5501842A, 5501868A, 5501882A, EXP APR-26; 5501957A, EXP MAY-26; 5502001A, EXP JUL-26; 5502033A, EXP AUG-26; 5502112A, 5502115A, EXP OCT-26; 5502180A, 5502181A, EXP NOV-26	The presence of a foreign substance, Benzene, in the product
4/9/2025	Class 2	Atorvastatin Calcium 40 Mg Tablets	BIOCON PHARMA INC	70377-0079-13	AVC24035, EXP 03/31/26	Failing to meet dissolution specifications, which may result in the tablets not dissolving properly

How do I find out more information about the recall? View the FDA website URL for more information.

RECALL TYPE	DRUG RECALLED	FDA NOTIFICATION URL
Class 2	Cinacalcet HCL 30 Mg Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=212863
Class 2	Cinacalcet HCL 60 Mg Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=212864
Class 2	Neupogen 300 MCG/ML Solution	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=212550
Class 2	Prasugrel HCL 5 Mg Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=212657
Class 2	Testosterone 25 Mg/2.5gm (1%) Gel	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=212808
Class 2	Testosterone 50 Mg/5gm (1%) Gel	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=212810
Class 2	Atorvastatin Calcium 40 Mg Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=213030